<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872857</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-0228</org_study_id>
    <nct_id>NCT02872857</nct_id>
  </id_info>
  <brief_title>Subarachnoid Hemorrhage Recovery And Galantamine</brief_title>
  <acronym>SAHRANG</acronym>
  <official_title>A Pilot Parallel Double-Blind, Randomized Trial of Galantamine for Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of the study drug--Galantamine—on
      patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH
      will tolerate the study drug and how it may improve brain functioning in patients after SAH.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability as assessed by the number of patients who stay on the study medication</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>baseline (in hospital), 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQOL score</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8mg galantamine twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12mg galantamine twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will match drug capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8mg galantamine twice daily</intervention_name>
    <description>Drug will be administered within 36 hours of hospitalization and continued for 90 days.</description>
    <arm_group_label>8mg galantamine twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12mg galantamine twice daily</intervention_name>
    <description>Drug will be administered within 36 hours of hospitalization and continued for 90 days.</description>
    <arm_group_label>12mg galantamine twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spontaneous subarachnoid hemorrhage

          -  Presentation to hospital within 72 hours of symptoms

          -  Fisher grade 3 hemorrhage (thick subarachnoid clot) on initial computed tomography
             (CT) scan

          -  Hunt and Hess grade 1-5 at time of randomization

          -  Presence of a cerebral aneurysm on computed tomographic angiography (CTA) or Angiogram
             for which clipping or coiling is possible

          -  Ability to obtain medication within 36 hours of presentation

        Exclusion Criteria:

          -  subarachnoid hemorrhage (SAH) due to causes other than aneurysm rupture (trauma,
             arteriovenous malformation (AVM), mycotic aneurysms, Moyamoya)

          -  Pre-existing disability with modified Rankin Scale (mRS) score ≥2,

          -  Renal disease as defined by creatinine clearance less than 9 milliliters/min

          -  History of severe hepatic impairment (Child-Pugh score of 10-15)

          -  History of chronic obstructive pulmonary disease (COPD) or asthma

          -  History of dementia

          -  Co-morbid conditions likely to complicate therapy, including clinically significant
             arrhythmia, acquired immune deficiency syndrome (AIDS), autoimmune disease,
             malignancy, and expected mortality within 72 hours

          -  Expected mortality within 72 hours as determined by PI, treating neurointensivist and
             neurosurgeon. (Clinically manifested by no attempt at securing aneurysm)

          -  Females who are pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huimahn Choi, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huimahn Choi, MD, MS</last_name>
    <phone>713-500-5638</phone>
    <email>Huimahn.A.Choi@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huimahn Choi, MD, MS</last_name>
      <phone>713-500-5638</phone>
      <email>Huimahn.A.Choi@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>HuiMahn Alex Choi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

